Affiliations 

  • 1 National Pharmaceutical Regulatory Agency, Ministry of Health, Malaysia, Petaling Jaya, Selangor, Malaysia
  • 2 Pfizer Inc., Medical Affairs, Kuala Lumpur, Malaysia
  • 3 Disease Control Division, Ministry of Health, Malaysia, Putrajaya, Malaysia
  • 4 Pfizer Inc, Emerging Markets Vaccines Medical and Scientific Affairs, Dubai, United Arab Emirates
Hum Vaccin Immunother, 2020 03 03;16(3):530-538.
PMID: 31652090 DOI: 10.1080/21645515.2019.1667206

Abstract

This review aims to present the unique considerations for manufacturing and the regulation of new vaccines in Muslim-populated countries such as Malaysia. Our specific objectives are to highlight vaccine production and the ingredients of concern, summarize the current mechanism for ruling and recommendations on new vaccines, outline the different steps in decision-making on incorporating a new vaccine into the National Immunization Program, describe its issues and challenges, and explore the commercial viability and challenges of producing local permissible (halal) vaccines. Through this review, we hope readers understand that alternatives are present to replace ingredients of concern in vaccines. Halal certification and introduction of a new vaccine into a program are strictly conducted and health-care providers must be prepared to educate the public on this. At the same time, it is hoped that the production of halal vaccine in Malaysia will promote self-reliance in Muslim-populated countries.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.